Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Medicus Pharma’s SEC disclosures can feel like decoding lab notes. Clinical endpoints, dose-escalation tables and financing covenants pack the company’s annual report—yet each detail can shift the valuation of this oncology-focused biotech overnight. If you have ever asked, “How do I get Medicus Pharma SEC filings explained simply?” you already know the challenge.
Stock Titan turns those dense documents into clarity. Our AI delivers line-by-line context so understanding Medicus Pharma SEC documents with AI becomes second nature. Need the Medicus Pharma annual report 10-K simplified or to monitor a sudden Medicus Pharma 8-K material events explained? It’s here, refreshed the instant EDGAR posts. Key tools include:
- Real-time alerts for every Medicus Pharma Form 4 insider transactions real-time
- Concise takeaways from each Medicus Pharma quarterly earnings report 10-Q filing
- AI-powered summaries that surface trial milestones, R&D spend and funding rounds
- Downloadable tables covering Medicus Pharma executive stock transactions Form 4
Whether you’re tracking basal-cell carcinoma trial progress or assessing dilution risk, our platform connects the dots. Investors use it to spot buying patterns in Medicus Pharma insider trading Form 4 transactions, compare cash burn across quarters with our Medicus Pharma earnings report filing analysis, or review the Medicus Pharma proxy statement executive compensation before casting votes. No more hunting through PDFs—just precise, AI-driven insight when it matters.
Medicus Pharma, Inc. (MDCX) filed an S-1 registration including a prospectus structure and partial financial schedules. The filing shows multiple equity issuances during 2024–2025: common shares and warrants were issued under a Regulation A offering with issuance costs of $483,020, and a later equity financing with net offering costs of $809,606. The company records repeated net loss and comprehensive loss for successive periods and reports stock-based compensation expense and share issuances upon warrant exercises. Financing activities include proceeds from common shares and warrants, debentures and convertible notes, with related issuance costs and non-cash adjustments. The cash flow section lists net cash used in operating activities and net cash provided by financing activities, and the balance sheet excerpts reference money market funds and debentures measured at fair value. The filing also discloses operating lease right-of-use assets and liabilities, valuation inputs for warrants/options, and certain redactions under Regulation S-K.
Patrick J. Mahaffy, a director of Medicus Pharma Ltd. (MDCX), reports beneficial ownership of 35,435 common shares and a stock option for 25,000 common shares exercisable through 08/29/2030 at an exercise price of $1.94. The option vests in equal quarterly installments over the 12 months following 08/29/2025. The Form 3 was signed by an attorney-in-fact on 09/08/2025.
Schedule 13G amendment filed by Armistice Capital, LLC and Steven Boyd discloses a shared beneficial ownership of 935,724 common shares of Medicus Pharma Ltd., representing 4.99% of the class. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder, and that Mr. Boyd, as managing member, may be deemed to beneficially own the shares. Voting and dispositive power are reported as shared (935,724 shares) with no sole voting or dispositive power.
FAQ
What is the current stock price of Medicus Pharma (MDCX)?
What is the market cap of Medicus Pharma (MDCX)?
